Entropy Technologies LP Purchases New Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Entropy Technologies LP acquired a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 13,750 shares of the company’s stock, valued at approximately $207,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. GAMMA Investing LLC increased its stake in shares of Pacira BioSciences by 229.6% during the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after purchasing an additional 932 shares during the period. Park Place Capital Corp bought a new position in Pacira BioSciences during the 2nd quarter worth $46,000. Innealta Capital LLC bought a new stake in shares of Pacira BioSciences in the second quarter valued at about $50,000. nVerses Capital LLC grew its stake in shares of Pacira BioSciences by 800.0% in the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock valued at $51,000 after acquiring an additional 1,600 shares in the last quarter. Finally, Natixis bought a new position in Pacira BioSciences during the first quarter worth about $95,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. StockNews.com downgraded shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. HC Wainwright reduced their price target on Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Raymond James cut Pacira BioSciences from an “outperform” rating to a “market perform” rating in a report on Monday, August 12th. JPMorgan Chase & Co. reissued an “underweight” rating and set a $10.00 target price (down from $45.00) on shares of Pacira BioSciences in a report on Monday, August 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Pacira BioSciences in a research note on Friday, November 8th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $23.50.

Pacira BioSciences Trading Up 1.4 %

PCRX opened at $16.60 on Monday. The company has a market cap of $766.47 million, a P/E ratio of -8.18 and a beta of 0.82. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The company’s 50 day moving average is $15.81 and its 200-day moving average is $20.64. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $35.95.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.